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ABSTRACT
Late diagnosis for Hepatocellular Carcinoma (HCC) remains one of the leading 
causes for the high mortality rate. The apurinic/apyrimidinic endonuclease 1 (APE1), 
an essential member of the base excision DNA repair (BER) pathway, contributes to 
cell response to oxidative stress and has other non-repair activities. In this study, 
we evaluate the role of serum APE1 (sAPE1) as a new diagnostic biomarker and we 
investigate the biological role for extracellular APE1 in HCC. sAPE1 level was quantified 
in 99 HCC patients, 50 non-HCC cirrhotic and 100 healthy controls. The expression level 
was significantly high in HCC (75.8 [67.3–87.9] pg/mL) compared to cirrhosis (29.8 
[18.3–36.5] pg/mL] and controls (10.8 [7.5–13.2] pg/mL) (p < 0.001). The sAPE1 
level corresponded with its protein expression in HCC tissue. sAPE1 had high diagnostic 
accuracy to differentiate HCC from cirrhotic (AUC = 0.87, sensitivity 88%, specificity 
71%, cut-off of 36.3 pg/mL) and healthy subjects (AUC 0.98, sensibility 98% and 
specificity 83%, cut-off of 19.0 pg/mL). Recombinant APE1, exogenously added to JHH6 
cells, significantly promotes IL-6 and IL-8 expression, suggesting a role of sAPE1 as a 
paracrine pro-inflammatory molecule, which may modulate the inflammatory status in 
cancer microenvironment. We described herein, for the first time to our knowledge, that 
sAPE1 might be considered as a promising diagnostic biomarker for HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) ranks sixth 
as the most frequent cancer worldwide [1] with more 
than 800,000 new cases diagnosed every year. The 
late diagnosis still remains one of the leading causes 
for the high mortality rate [1]. The recent molecular 
characterization of the disease [2] provided new insights 
into the cellular networks involved in hepatocarcinogenesis 
becoming a source of potential new therapeutic targets as 
well as new biomarker to use in a clinical setting.
DNA repair pathways play a significant role in 
the cellular and organismal response to environmental 
exposure by maintaining the genome integrity and thus 
helping to prevent the onset of disease, aging phenotypes, 
and cancer development. Tumor cells can develop drug 
resistance via repair mechanisms that counteract the DNA 
damage from chemotherapy or radiation therapy, and DNA 
repair enzymes are emerging targets for novel anticancer 
strategies [3, 4]. 
The base excision DNA repair (BER) pathway 
handles simple alkylation and oxidative lesions arising 
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from both endogenous and exogenous sources, including 
cancer therapy agents [5]. The essential BER enzyme, 
the apurinic/apyrimidinic endonuclease 1 (APE1), 
contributes to the regulation of oxidative stress responses 
and has other non-repair activities, such as regulating 
the expression of chemoresistance genes through 
direct and indirect mechanisms [6, 7]. By using APE1 
knock-down models, we and others have demonstrated 
the pleiotropic ability of this protein to regulate the 
expression of hundreds of genes, involved in different 
biological processes, which are associated with cancer 
cell proliferation, invasion and drug resistance [8–11]. 
Interestingly, accumulating evidences indicate that APE1 
may control gene expression via unsuspected functions in 
RNA metabolism [5, 12, 13] including miRNA expression 
[10], thus enhancing APE1 critical functions in tumor 
progression. 
Well-known features linking APE1 and tumor 
development are its over-expression in many tumors and 
the correlation with the onset of chemoresistance in HCC 
and Non-Small Cell Lung Cancer (NSCLC), as well as 
neurologic, ovarian and breast tumors [11, 14]. Notably, 
its inhibition or down-regulation sensitizes cancer cells 
to DNA-damaging chemotherapeutic drugs and ionizing 
radiation [15]. Interestingly, a recent pioneering study 
found that plasmatic APE1 may represent a biomarker 
for predicting prognosis and therapeutic efficacy in 
NSCLC [16]. In fact, the chemotherapy-naïve serum 
APE1 level, which correlates with its tissue level, is 
inversely associated with progression-free survival of 
platinum-containing doublet chemotherapy; whereas post-
treatment serum APE1 level is inversely associated with 
overall survival [16]. Interestingly, increasing evidences 
support the finding that extracellular APE1 secretion is 
a common feature of cancer cells, while the biological 
meaning remains to be elucidated but could be associated 
to triggering the inflammatory response of cancer 
microenvironment [17–19].
Despite several findings that associated APE1 to 
chemo- and radio resistance in tumors [16], marginal 
information exists in HCC. From our previous studies 
performed in cancer tissue biopsies, we defined a 
prognostic role for APE1 expression in HCC [20, 21]; 
however, nobody still evaluated the expression of APE1 
in serum (sAPE1) of HCC patients. 
Considering all these observations, we checked 
whether sAPE1 may serve as a biomarker for HCC. This 
work was undertaken to answer this issue and could 
represent a further step in biomarker discovery associated 
to patient’s prognosis, helpful to ameliorate therapy 
efficacy. Also, we show here that extracellular APE1 may 
contribute to triggering a pro-inflammatory state being 
able to promote IL-8 expression in a hepatic cancer cell 
line. Our novel findings open new perspectives in HCC 
biomarker discovery as well as APE1 functional role in 
cancer development.
RESULTS
Baseline characteristics
The demographic features of the groups are shown 
in Table 1. The participants were predominantly male 
(78%, 62%, and 71%) with a median age of 72, 67, and 
56 years, respectively (p < 0.001). The etiology of chronic 
liver disease was alcohol abuse and/or metabolic in the 
majority of HCC and cirrhotic patients (55% and 40%, 
respectively), while viral hepatitis was in 23% and 16%. 
As of cirrhosis severity, most of the patients were 
CTP score A for 74% and 80%, whereas it was B or C in 
23% and 20% for HCC and cirrhosis group, respectively. No 
significant difference was noticed between the two groups.
In HCC group BCLC 0, A, B, C/D scores were 
recorded in 7%, 59%, 26%, and 7% of patients, 
respectively. Regarding the prognosis scores, GRETCH 
score was intermediate in most patients (68%), low in 
15%, and high in only 1%. CLIP score distribution appears 
to be more homogeneous, with a score 0 in 27% of the 
patients, score 1 in 32%, score 2 in 16%, and score 3/4 
in 9%. As regards ITA.LI.CA Prognostic, score 2 was in 
44%, score 3 in 21%, score 4 in 12%, and score >5 in 7%. 
ECOG score was 0 in the vast majority of HCC patients 
(85%), score 1 in 7%, and score 2/3 in 5% of the study 
group. No statistical differences exist among all groups.
In HCC group, tumor mass, number of lesions, and the 
level of alpha-fetoprotein (AFP) were recorded. With respect 
to tumor mass and number of lesions, 15% subjects showed 
a single nodule smaller or equal to 2 cm in diameter, 47% 
had either a single nodule ranging 2 to 5 cm, or 2–3 nodules 
up to 3 cm each, while 37% had single nodule larger than 
5 cm in diameter or multifocal. As for AFP level, 53% had 
AFP level lower than 20 ng/mL, 13% between 20 ng/mL 
and 400 ng/mL, and 12% with AFP level above 400 ng/mL.
Serum APE1 level significantly distinguishes 
HCC from cirrhotic patients and healthy subjects
The level of sAPE1 was measured by ELISA and 
expressed as median (95% CI), as previously described 
[16]. As a validation of the specificity of the ELISA assays 
used, we included a pool of blood donors’ sera spiked with 
different concentrations of recombinant purified APE1 
protein (data not shown). 
The highest concentration of sAPE1 was found in 
HCC, with median concentration of 75.8 (67.3–87.9) pg/
mL with a minimum and maximum value of 15.2 and 
881.4 pg/mL, respectively, and it was significantly higher 
(p < 0.001) compared to median concentration in either 
cirrhosis (29.8; 18.3–36.5 pg/mL) or healthy blood donors 
of (10.8; 7.5–13.2) (Figure 1A). sAPE1 was undetectable 
in 36 (36%) of healthy and in 10 (20%) of cirrhotic 
samples. A significant difference was observed also in 
cirrhosis compared to healthy control (p < 0.001). 
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Circulating sAPE1 as diagnostic biomarker for HCC
When considering the diagnostic value of sAPE1, 
the area under the curve (AUC) of the receiver operator 
characteristic (ROC) curve was 0.87 (0.78–0.92) 
(Figure 1B). Using a cut-off of 36.3 pg/mL, sAPE1 can 
distinguish HCC patients from cirrhotic subjects with 
sensitivity and specificity of 88% and 71%, respectively. 
When considering the predictive value of sAPE1 in 
distinguishing HCC patients from healthy subjects, the 
AUC score improves to 0.98 (0.96–0.99) (Figure 1C). At 
a cut-off determined at 19.0 pg/mL, the sensibility and 
specificity increased to 98% and 83%, respectively.
sAPE1 level in HCC is associated with viral 
infection but not with other clinical parameters
 sAPE1 levels were significantly higher when 
comparing HCC-related viral infection to other non-viral 
etiologies (p < 0.001). In patients with either viral hepatitis 
C or B infection, the median sAPE1 was 98.8 (85.4–141.1). 
However, highest sAPE1 level was observed in patients 
with multiple etiologies (viral, metabolic, and alcohol) 
with median concentration of 132.37 (84.3–208.2).
The association of sAPE1 level and clinical and 
pathological characteristics of HCC patients was shown 
in Table 2. With respect to HCC staging and prognostic 
scores, there was a significant correlation between sAPE1 
and GRETCH score, but not with any other HCC scores. 
No correlation with other clinical parameters, such as AFP, 
transaminases, transferrin, albumin, and insulin was observed. 
APE1 expression is higher in HCC compared to 
its surrounding and normal tissue
In order to determine whether high sAPE1 levels 
found in HCC tumor samples correlate with an overall 
overexpression of APE1 both at protein and mRNA 
levels, Western blot analysis and qPCR were performed 
in non-tumor and tumor tissue of liver cancer. APE1 
mRNA expression was analyzed in 59 tissues from 24 
HCC patients, and 4 normal liver (CTRL). As shown in 
Table 1: Demographic characteristics of the study populations
HCC Cirrhosis Healthy P value
Patients characteristics
Age (mean, 95%CI) 71 (68.8–72.1) 66 (63.6–68.3) 56 (55.1–56.6) <0.001
Sex (M/F) 77/22 31/19 71/29 ns
Etiology ns
Alcohol metabolic 54 20
Alcohol metabolic viral 18 17
Viral 23 8
Other* 4 5
Disease scores
CTP A/B/C 73/20/3 40/7/3 ns
BCLC 0/A/B/C–D 7/58/26/6 
ECOG 0/1/2–3 84/7/5
GRETCH Low/Intermediate/High 15/67/1
CLIP 0/1/2/3–4 27/32/16/9
ITA.LI.CA Prognostic 2/3/4/5–8 44/21/12/7
Tumor parameters
Number of lesions
Single <2 cm 15
Single or 3 <3 cm 46
Large-single or multi 37
Alpha fetoprotein
<20 ng/mL 52
20–400 ng/mL 13
>400 ng/mL 12
*autoimmune, hemochromatosis, cryptogenic, usually in combination with other.
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Figure 2A, an increase of APE1 mRNA was observed in 
HCC as compared either to the SLC and peri-HCC or also 
to normal liver (CTRL). When the mRNA expression was 
compared in paired samples of HCC to its corresponding 
SLC and peri-HCC, the ratio of mRNA up-regulation 
between HCC/SLC and HCC/peri-HCC was 4.9 ± 6.9 and 
5.8 ± 11.3-fold, respectively. 
APE1 protein levels were quantified in tissues 
from patients with high sAPE1 levels. Analysis were 
performed either within single patients (Figure 2B and 
Supplementary Figure 1) and pooled samples (Figure 
2C). APE1 protein expression levels were determined by 
densitometric scanning of the immunoreactive bands and 
normalized against actin loading control. Besides the full-
length protein band, a truncated form of the protein was 
detectable (Figure 2C), corresponding to a proteolytic form 
called NΔ33 (Supplementary Figure 2) [22]. A significant 
increase of APE1 total protein was observed in tumor 
samples, particularly in the full-length form (Figure 2C). 
These results were confirmed by immunohistochemistry 
staining (Figure 2D), where APE1 protein resulted highly 
expressed in the HCC nodule compared to its paired SLC, 
Figure 1: sAPE1 level in circulation. (A) circulating sAPE levels in healthy blood donors, cirrhosis and HCC groups. ***P < 0.001 
among groups. (B) ROC curve for HCC diagnostic from cirrhosis with AUC score of 0.87 (0.78–0.92, 95%CI) with 36.3 pg/mL as a cut-off. 
(C) ROC curve for HCC diagnostic from healthy blood donors with AUC score of 0.98 (0.96–0.99, 95%CI) with 19.0 pg/mL as a cut-off. 
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while it was not noticed in normal liver. In SLC, the positivity 
of APE1 was mostly noticed in the nucleus, while in HCC 
tissues, both strong nuclear and cytoplasmic expressions were 
detected. To check whether the sAPE1 might be correlated 
with its expression in HCC nodule, the level of sAPE1 
and hepatic APE1 protein were compared within the same 
patients. As shown in Figure 2E, the high sAPE1 expression 
corresponded with that found in HCC nodules.
Table 2: sAPE1 level and its association with clinical and pathological characteristics of the HCC 
group
sAPE1 (pg/mL)
Count Median (95% CI) p value
Age ns
<72 52 74.2 (60.5–96.4)
>72 47 78.8 (66.2–103.7)
Sex ns
Male 77 73.9 (63.2–87.2)
Female 22 97.1 (65.0–122.9)
Etiology <0.001
Alcohol metabolic 54 62.6 (48.6–73.9)
Alcohol metabolic viral 18 132.37 (84.3–208.2)
Viral 23 98.8 (85.4–141.1)
Other* 4 63.2
CTP ns
A 73 78.8 (65.0–96.4)
B/C 23 70.76 (44.5–128.6)
BCLC ns
0-A 65 77.3 (60.5–96.4)
B-C-D 32 74.5 (48.6–101.3)
GRETCH <0.05
Low 15 60.5 (33.0–101.3)
Intermediate-high 68 83.2 (68.1–91.1)
CLIP ns
0–1 59 78.7 (67.3–97.7)
2–3–4 25 71.6 (56.1–114.7)
ITA.LI.CA prognostic ns
2 44 87.1 (69.7–107.8)
3 21 74.6 (56.1–108.7)
4 12 53.5 (32.3–159.2)
5–8 7 71.6 (40.3–138.3)
Number of lesions ns
Single <2 cm 15 86.9 (43.8–120.4)
Single or 3 <3 cm 46 74.6 (60.5–117.9)
Large-single or multi 37 74.5 (61.2–89.5)
AFP ns
<20 ng/mL 52 76.7 (65–87.2)
20–400 ng/mL 13 138.3 (37.1–179.9)
>400 ng/mL 12 80.5 (43.8–122.9)
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Recombinant exogenously added APE1 protein 
promotes the expression of IL-6 and IL-8 genes 
in JHH-6 cell line
In order to evaluate a possible role for secreted 
APE1 in HCC, we tested whether exogenous addition of 
recombinant purified APE1 (rAPE1) may trigger a pro-
inflammatory status in JHH-6 HCC cell line, as recently 
demonstrated in human monocytes cell lines [19]. In 
addition to the wild-type protein (rAPE1WT), we used 
an acetylated-mimicking mutant on residues 27, 31, 
32, 35 (rAPE1K4pleA), in which Lys residues have been 
replaced by Ala, as described before [23, 24] and whose 
relevance in cancer have been recently demonstrated [22] 
(Supplementary Figure 3). As previously described, cells 
were treated for 24 hours with two doses of recombinant 
Figure 2: APE1 expression in HCC tissues. (A) qPCR of tumor (HCC), peri-HCC, and surrounding liver cirrhosis (SLC), and 
normal liver (CTRL) (left panel). Ratio between HCC and SLC and HCC and peri-HCC within the same patients (right panel). APE1 
mRNA quantification was normalized to two reference genes 18srRNA and Actin. Bar graphs indicate mean and SEM. (B) APE1 protein 
quantification in HCC and SLC tissue lysates from HCC cancer patients. Graphs indicate the different distributions of the fold of protein 
expression for each sample as the ratio between APE1 and actin. (see Supplementary Figure 1). *P < 0.05. (C) Western blot analysis 
of HCC and SLC tissue lysates patients performed on pooled samples from HCC cancer. Actin was used as loading control and for the 
relative normalization. A representative image of western blot analysis is shown. Data represent the means of ± SD of three independent 
experiments. *P < 0.05. (D) Immunohistochemistry of HCC, SLC, and normal (CTRL) tissue. Red and yellow arrows indicate nuclear and 
cytoplasmic positivity, respectively. (E) Scan of HCC nodules and its corresponding sAPE1 from 3 patients representing for each low, 
median, and high sAPE1. 
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purified proteins, and the expression of IL-6 and IL-8 
genes was assayed by qPCR. APE1 recombinant proteins 
induced an upregulation of both cytokines in treated 
cells; the rAPE1K4pleA promoted a higher increase of 
IL-6/IL-8 compared to rAPE1WT (Figure 3A). The cells 
responsiveness to a proinflammatory stimulation was 
verified by treating cells with rTNF-α (Figure 3B). This 
stimulatory activity of rAPE1 was also confirmed, even 
to different extents, in other cancer cell lines, such as: 
A549 from lung cancer, confirming the generality of 
this phenomenon that requires further additional careful 
characterization. However, we checked the stimulatory 
activity by rAPE1 using also GST-tagged rAPE1 as well 
as recombinant Glutathione –S-Transferase (a bacterial 
protein) alone obtained from the same E. coli strain. Data 
obtained (not shown) clearly demonstrated that, while 
GST-APE1 exerts the same stimulatory activity of rAPE1, 
the GST alone did not produce any effect on IL-6/-8 
induction, eliminating the possibility of IL-6/-8 induction 
by any contaminating LPS or other proteins. These data 
suggest a role of sAPE1 as a paracrine pro-inflammatory 
molecule, which may modulate the inflammatory status in 
cancer microenvironment. However, in clinical samples 
there were not significant correlation between sAPE1 
with both IL-6 and IL-8 levels in sera and in tissues 
(Supplementary Figures 4 and 5). 
DISCUSSION
In the present study, we found that sAPE1 protein, 
an essential DNA repair enzyme in the BER pathway, 
could be a promising diagnostic biomarker for HCC 
patients. Interestingly, this previously reported nuclear 
protein has been recently detected in the serum of patients 
of coronary artery disease [25] and bladder cancer patients 
where its level correlated with the level measured in 
cancer tissue [26]. More recently, this unexpected finding 
was confirmed in the plasma of both lipopolysaccharides-
induced endotoxemic rats [27] and in NSCLC human 
patients [16], opening new perspectives in understanding 
the many functions of this unusual DNA repair protein 
in different conditions associated to oxidative stress and 
cancer development. We report that the sAPE1 levels 
correlate with its level in HCC tissue, in line with previous 
findings in non-small cell lung cancer [16]. 
The secretion of this protein seems to be a regulated 
phenomenon, depending on acetylation occurring on 
specific Lysine residues [17]. The biological relevance 
of secreted APE1 is still a matter of debate. It has been 
demonstrated that acetylated-APE1 may trigger apoptosis 
in TNBC cells by binding to the receptor for advanced 
glycation end products (RAGE) [28]. Other recent data 
demonstrated that the redox-function of APE1 may 
contribute to the control of the inflammatory response by 
inhibiting the TNF-α-induced endothelial inflammation 
via thiol-disulfide exchange in TNFR [18]. Moreover, 
very recently, a role for extracellular APE1 in the control 
of early stages of inflammation processes has been 
proposed [19]. Treatment of human THP-1 and RAW264.7 
monocytes with rAPE1 increased the expression and 
secretion of the pro-inflammatory cytokine IL-6, through 
the involvement of NF-κB transcriptional activation, 
eliciting an autocrine/paracrine cellular response in a 
functional feedforward loop between APE1 and IL-6 
regulation. However, detailed information regarding 
the mechanism responsible of APE1 release is still 
controversial, though it seems plausible that it might occur 
through extracellular vesicles formation via endosomal 
sorting complex [19].
Therefore, as a mainly nuclear protein, the source 
of sAPE1, whether it be from normal or cancer cells, 
is currently unknown and it is the focus of ongoing 
investigations. In our present study, we show a direct 
correlation between serum and tissue APE1 levels in 
the cohort we analyzed. We already described that the 
cytoplasmic expression of the protein in HCC patients 
correlates with poor prognosis, but we could not provide a 
significant biological role for cytoplasmic APE1 in HCC 
[20]. APE1 is a non-canonical secretory protein lacking 
a classic secretory signal based on protein sequence 
analysis. Intriguingly, several reports showed that APE1 
is secreted under specific stimuli, such as those provided 
by Trichostatin-A [17] and LPS [19, 27]. According to 
these studies, secretion of APE1 was associated with its 
cytoplasmic translocation; however, in the present study, 
we failed to find a positive correlation between sAPE1 
and its cytoplasmic distribution in HCC. Future work is 
warranted to inspect the secretory pathway of APE1 and 
its biological relevance. We believe that a passive release 
of sAPE1 by a necrotic process is unlikely, as its level 
does not correlate with any of the markers of liver damage 
analyzed. Moreover, cultured JHH-6 liver cancer cell lines 
do actively secrete APE1 in the culture media (data not 
shown) supporting the hypothesis that sAPE1 derives 
from an active secretion process involving, for instance, 
an exosomal pathway. Work is ongoing in our lab along 
this line to test this hypothesis.
Regarding the biological relevance of APE1 
secretion, we found that recombinant exogenously added 
rAPE1 is able to promote IL-6/8 gene expression in JHH-
6 HCC cell line. Two of the major pro-inflammatory 
cytokines secreted by senescent cells, IL-6 and IL-8, may 
function either to reinforce senescence [29] or to promote 
tumor invasiveness [30]. Thereafter, regulation of the 
inflammatory environment may have a critical role in 
determining the fate of both senescent and proliferating 
tumor cells. Based on the evidence that exogenous rAPE1 
may trigger expression of both IL-6/8 cytokines, we may 
hypothesize that secreted APE1 may act as a paracrine 
molecule in regulating tumor microenvironment cell 
decision fates. These findings provide new insight into 
the underlying the clinical and biological relevance of 
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Figure 3: Recombinant APE1 promotes IL-6 and IL-8 mRNA expression in JHH-6 HCC cell line. (A) JHH-6 cells were 
treated for 24 h in serum free medium with recombinant rAPE1WT and rAPE1K4pleA proteins (1–2 μg/ml concentration). 24 h serum free 
medium JHH-6 cells were used as a control (CTR). Performed qPCR analyses show that rAPE1K4pleA recombinant protein promotes an 
induction of IL-6 and IL-8 mRNA expression levels. (B) IL-6 and IL-8 induction in JHH-6 TNF-α treated cells. JHH-6 cells were treated for 
3 h in serum free medium with TNF-α (2000 U/ml concentration). Performed qPCR analyses show the induction of IL-6 and IL-8 mRNA 
expression mediated by TNF-α. Statistical analyses were achieved by using Two-way ANOVA test.
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circulating sAPE1, however, future work is needed to 
address these issues, which may have a strong relevance 
in the clinics of HCC prognosis and therapy.
MATERIALS AND METHODS
Patients 
This case-control study was conducted in patients 
referring to the Liver Center of the University Hospital of 
Trieste, Italy. Fasting blood samples were collected in three 
groups: 99 consecutive patients patients observed between 
2008 and 2018 whose HCC was diagnosed according to 
the EASL criteria [31]; 50 consecutive patients with 
cirrhosis confirmed by imaging, elastography, blood 
tests, and/or histological evaluation, without echographic 
evidence of HCC observed between April and June 2018; 
100 consecutive healthy blood donors recruited in 2018 at 
the Transfusion Clinic.
Cirrhosis and HCC groups were further defined 
according to Child-Turcotte-Pugh score (CTP) and 
etiology (i.e. viral, alcoholic, metabolic, and other 
uncommon etiologies). For HCC group, classifications 
of Barcelona Clinic Liver Cancer (BCLC) [31], Eastern 
Cooperative Oncology Group (ECOG) [32], GRoupe 
d’Etude et de Traitement du Carcinoma Hépatocellulaire 
(GRETCH) [33], Cancer of Liver Italian Program (CLIP) 
[34], and the Italian Liver Cancer (ITA.LI.CA) [35] 
prognostic were defined. HCC samples were collected at 
the time of diagnosis, before any oncological treatment. 
Exclusion criteria for all groups were age lower 
than 18 years old, pregnancy, and other malignancies. 
All the patients provided written informed consent and 
patient anonymity has been preserved. Investigation was 
conducted according to the principles expressed in the 
Declaration of Helsinki. The study was approved by the 
regional ethical committee (Comitato Etico Regionale 
Unico del Friuli Venezia Giulia, Prot. No. 2018 Os-008-
ASUITS, CINECA no. 2225). 
Serum samples collection and sAPE1 quantification
Serum samples were collected in Vacuette® tubes, 
centrifuged at 3500 rpm for 10 min and stored at –80°C 
until use. Hemolyzed samples were discarded from 
the analysis. Hemoglobin in serum was assessed with 
Beckman Coulter®DU®730 spectrophotometer using the 
Harboe Direct method [36] with Allen correction [37]. 
The considered cut-off for serum was 0.040 g/L. sAPE1 
levels were determined using Human APEX1 ELISA kit 
(Cusabio, Houston, USA). The optical density (OD) was 
detected with an EnSpire microplate reader (PerkinElmer, 
Waltham, USA), at a wavelength of 450 nm with a 
correction set at 540 nm. sAPE1 levels (pg/mL) were then 
calculated by using a standard linear regression curve 
fitting by NCSS 11 Statistical Software (2016) (NCSS, 
LLC. Kaysville, USA). To determine the specificity of the 
test we spiked into blood donors’ serum 62.5 and 31.25 
pg/mL of rAPEX1. We use the curve-fitting model built 
on OD vs sAPE1 concentration (pg/mL) to estimate the 
concentration of the two spiked samples (data not shown).
HCC tissues collection and hepatic APE1 mRNA 
and protein expression 
Fresh hepatic tissues were collected from HCC 
patients undergoing liver resection without any prior 
treatments. Samples consisted of HCC nodule, peri-
HCC and surrounding liver cirrhosis (SLC). Tissues were 
quickly snap-frozen and stored in –80°C. 
Real time PCR
Total RNA was extracted using TriReagent (Sigma–
Aldrich) and reversed transcribed using the iScript cDNA 
synthesis Kit (Bio-Rad Laboratories, Hercules, USA) 
according to the manufactures’ protocols. Reactions were 
run on IQ5 PCR detection system (Bio-Rad). 
Western blot
Lysates were resolved on 12% SDS-PAGE, 
transferred onto nitrocellulose membranes (Amersham™ 
Protran™, GE Healthcare) and probed with antibodies for 
APE1 (NB 100-116, Novus Biologicals, USA) (1:1000), 
APE1 N-terminal 1-14 aa specific goat polyclonal 
Antibody (NB100-897, Novus Biologicals) (1:2000) and 
actin (A2066, Sigma–Aldrich) (1:2000) as internal control. 
The IR-Dye labelled secondary antibodies (anti-rabbit IgG 
IRDye 680 and anti-mouse IgG IRDye 800) were used. 
Detection and quantification was performed with the 
Odyssey CLx Infrared imaging system (LI-COR GmbH, 
Germany). The membranes were scanned in two different 
channels using an Odyssey IR imager; protein bands were 
quantified using Odyssey software (Image Studio 5.0) and 
the relative signal was calculated.
Immunohistochemistry 
Paraffined hepatic slices were de-paraffinized 
with xylene and rehydrated with gradual concentration 
of ethanol. Tissues were incubated with APE1 antibody 
(NB100-101, Novus Biologicals, USA) followed by 
incubation with primary universal antibody enhancer and 
HRP polymer (Thermo Fisher Scientific, Cheshire, UK). 
The complex was visualized with the DBA peroxidase 
substrate kit (Vector Laboratories, UK) and nucleus was 
stained with hematoxylin. Slides were scanned by using 
Zenit G Sight 2.0 (A.Menarini Diagnostics, Italy) and 
images were generated using two microscopical systems 
Leica DM2000 (Leica, Wetzlar, Germany) and Zenit G 
Sight 2.0.
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Cell culture and treatments
JHH-6, an undifferentiated HCC cell line, were 
grown in William’s medium E (Sigma–Aldrich), 
supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin, 100 μg/ml streptomycin (Euroclone, Milan, 
Italy). A total of 1.5 × 105 JHH-6 cells were seeded in six-
well plate for 24 h. For rAPE1 treatment, cells were treated 
for 24 h with rAPE1WT or rAPE1K4pleA with concentrations 
1 μg/mL and 2 μg/mL in serum-free medium. While for 
TNF-α treatment, cells were treated with recombinant 
human TNF-α (Peprotech Inc., Rocky Hill, NJ) in serum-
free medium using the same condition reported in [38].
Total RNA was extracted from JHH-6 treated cells using 
NucleoSpin® RNA kit (Machery Nagel, Düren, Germany) 
according to the manufacturer’s instructions and reverse 
transcribed using SensiFAST cDNA Synthesis Kit (Bioline 
GmbH, Luckenwalde, Germany). qRT-PCR was performed 
with CFX96 Real-Time System, using SensiFAST™ SYBR® 
No-ROX Kit (Bioline GmbH, Luckenwalde, Germany). 
APEX, IL6 and IL8 mRNA expressions were normalized 
to GAPDH and HPRT expression. The primers used were 
included in Supplementary Table 1.
Recombinant APE1 protein expression and FPLC 
purification
Expression and purification of rAPE1 proteins from 
E. coli were performed as previously described [24, 39]. 
Briefly, E. coli BL21(DE3) cells were transformed with 
the construct pGex2T-APE1, coding for the glutathione 
S-transferase (GST)-APE1 full-length protein and for the 
APE1 acetylated mutant (K27A, K31A, K32A, K35A) and 
induced for 4 hours with 1.0 mM IPTG (Sigma–Aldrich) 
and collected upon centrifugation. The pellet was lysed 
and sonicated in the presence of protease inhibitor 2.1 mg/
mL and Lysozyme 0.3 mg/mL. Samples were centrifuged 
at 23000 g for 20 minutes at 4°C, the supernatants were 
filtered and FPLC purified.
GST-tagged proteins were purified through a 
GSTrap column (GE Healthcare) and they were eluted 
in an increasing range of GSH concentration following 
the manufacturer’s instructions. The proteins were 
incubated with Factor X (Amersham) to remove the tag 
and separated from the enzyme through a benzamidine 
column (GE Healthcare). A cation exchange purification 
was performed. The fractions were pooled together and 
stored in buffer containing 25 mM Tris pH 7.5, 100 mM 
NaCl, 1 mM DTT, and 10% glycerol.
Statistical analysis
Serum APE1 differences in a pairwise comparison 
were calculated by Mann–Whitney U. Differences among 
groups were calculated by Kruskal-Wallis test in one way 
ANOVA, with Bonferroni correction. The receiver operating 
characteristic (ROC) curves were plotted to estimate the 
diagnostic value of sAPE1. Analyses were performed by 
using NCSS 11 Software (2016) (NCSS, LLC. Kaysville, 
Utah, USA, https://www.ncss.com/software/ncss/).
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